Q1 2026 sales were $1.928B, adjusted operating margin was 26.8%, and operating cash flow was $451.5M.
From Portfolio Manager reports
Security report / AME
AME Operating Console
AMETEK remains a high-quality industrial technology compounder, but the current read is no longer just steady execution. Q1 2026 orders, margins, cash conversion, and raised guidance support the premium frame, while the pending Indicor acquisition turns the next proof window toward leverage, integration, return quality, and adjusted-to-GAAP cash validation.
Selected-Security Chart
Loading AME daily chart from the local report API.
Loading AME chart...
Current Company View
The $5.0B Indicor deal and $4.0B delayed-draw term loan shift the debate to leverage, integration, and return discipline.
The July 2, 2026 local close of $234.62 implies roughly 29x the $8.04 FY2026 adjusted EPS guidance midpoint.
Watch Q2 earnings, book-to-bill, backlog conversion, segment margin bridge, free cash flow, debt cost, and pro forma leverage.
Selected Security Trade Plan
Business Profile, Segments, And Exposure
AMETEK is a diversified industrial technology company with two operating groups and a larger pending acquisition test.
Business model
EIG sells analytical, test, and measurement instrumentation. EMG sells engineered components, MRO services, precision motion, thermal management, specialty metals, interconnects, and medical or aerospace products.
Disclosure map
EIG and EMG segment sales and operating income are disclosed. Indicor pro forma margins, purchase accounting, synergies, debt cost, and leverage are not yet reported.
EIG profit engine
EIG contributed about two-thirds of Q1 sales and nearly 69% of disclosed segment operating income before corporate expense.
Order conversion, segment margin durability, organic growth, and cost pass-through commentary.
EMG leverage
EMG is smaller than EIG, but the Q1 release showed strong operating leverage and First Aviation adds aerospace and MRO exposure.
Whether margin expansion repeats under tariff, freight, component, and integration pressure.
Indicor
The announced acquisition adds about $1.1B of annual sales, but the $5.0B price makes returns and leverage the central medium-term evidence.
Close terms, debt draw, interest cost, pro forma leverage, margin, recurring revenue, and integration cost disclosures.
Industrial channels
Order visibility, niche pricing power, and aerospace/MRO demand help, while restrictive rates, tariffs, freight, components, and shipping risk still matter.
Official orders, supplier delivery data, import cost pressure, and aerospace or defense conversion.
Relative Value And Value Drivers
The multiple can stay quality-backed only if operating proof and acquisition proof arrive together.
High-single-digit FY2026 sales guidance needs Q2 and Q3 conversion, not just order intake.
Next: book-to-bill, backlog, organic sales, and Q2 guide update.EIG mix and EMG leverage support the premium frame if cost and integration pressure stay contained.
Next: segment bridge, core margin, tariff and freight commentary.Cash generation is the main support for deleveraging, dividends, and acquisition funding.
Next: working capital, capex, free cash flow, and adjusted-to-GAAP reconciliation.The acquisition can add quality scale, but debt cost and integration results decide whether returns stay durable.
Next: close status, tranche draw, debt cost, leverage, synergies, and purchase accounting.Guidance Path And What Changed
Q1 guidance was constructive, but the next update must bridge standalone strength to acquisition-financed execution.
Confirm Q2 and Q3 orders, backlog conversion, and organic sales support high-single-digit FY2026 growth.
Warn if book-to-bill, backlog, or segment sales decelerate without a clean demand bridge.
Confirm segment margins remain near Q1 levels with contained component, freight, tariff, and mix pressure.
Warn if adjusted margin stability depends on recurring add-backs or weak GAAP conversion.
Confirm close disclosures show manageable leverage, reasonable debt cost, clean integration costs, and margin-consistent acquired economics.
Warn if pro forma economics remain opaque after close or if debt cost reduces capital-allocation flexibility.
Operating Evidence And KPIs
These tiles are the operating evidence checks for the next source occurrence.
Q1 2026 sales rose 11%; the guide needs high-single-digit FY2026 sales growth to remain credible.
The Q1 release cited record orders and backlog, making conversion the highest-signal near-term KPI.
Adjusted operating margin was close to GAAP operating margin, but acquisition adjustments need monitoring.
Q1 operating cash flow less capex supports the deleveraging and acquisition-capacity case.
Financial Quality And Capital Allocation
Pre-Indicor quality is strong; post-close quality depends on leverage, integration costs, and cash conversion.
Financial quality
FY2025 operating cash flow of $1.802B exceeded net income of $1.480B. Q1 2026 operating cash flow of $451.5M exceeded net income of $399.4M, with low capex relative to sales.
Capital allocation
FY2025 included $933.2M of business purchases, $434.0M of repurchases, and $285.3M of dividends. Indicor is large enough to compete with buybacks until leverage normalizes.
Competitive Position
The evidence supports a narrow edge, with the acquisition model now under a larger proof test.
What AMETEK has
EIG and EMG segment economics support differentiated instrumentation and engineered-product positions.
Capex was modest relative to sales in FY2025 and Q1 2026, supporting cash deployment flexibility.
Recurring acquisition deployment is part of the AMETEK model and supports growth when returns remain disciplined.
What is not proven
Pro forma margin, leverage, debt cost, synergies, purchase accounting, and integration costs are not yet reported.
The latest source pair does not include a full peer filing, call, or valuation comparison.
Full last-four-quarter earnings-call transcripts were not retrieved, limiting Q&A and narrative-drift confidence.
Ownership, Flows, Valuation, And Street View
Use dated official links and local market data as context, not as live consensus evidence.
AMETEK lists 15 covering firms
Checked 2026-07-05: AMETEK's analyst coverage page listed firms including Baird, BofA, KeyBanc, Mizuho, Oppenheimer, RBC, TD Cowen, Truist, Vertical, and Wolfe.
Dashboard use: coverage breadth, not a rating or target source. AMETEK IR analyst coverage$234.62 close
Local data through July 2, 2026 showed AME up 5.0% over one month, 12.2% year to date, and 28.9% over one year.
Dashboard use: the market is already underwriting quality and clean execution. Fallback chartRoughly 29x FY2026 adjusted EPS midpoint
The valuation can be justified by durable margins and cash conversion, but it leaves less room for Indicor or adjusted-quality slippage.
Dashboard use: separate company quality from price tolerance. Metadata source trailLow short-interest signal
Proxy evidence showed Vanguard at 11.0% and BlackRock at 7.5%; local short interest was about 1.5% of weighted shares on June 15, 2026.
Dashboard use: capital allocation and leverage matter more than short pressure. Knowledge laneScenario Assessment And Sensitivities
Scenarios hinge on whether strong standalone execution and Indicor evidence arrive together.
Backlog converts, margins stay premium, cash conversion remains strong, and Indicor closes with manageable financing and integration signals.
Orders broaden, cost pressure stays contained, aerospace and MRO support persists, and Indicor disclosures reduce the leverage and return burden.
Orders soften, cost pass-through fails, debt costs rise, or Indicor integration and adjusted-to-GAAP divergence compress the premium multiple.
Monitoring Triggers
These are business evidence checks. Chart overlays remain in the shared overlay rules, outside this page.
Backlog conversion versus guide
Confirm high-single-digit FY2026 sales growth with orders and backlog converting into reported revenue.
Warn if orders, book-to-bill, backlog, or segment sales weaken while guidance stays unsupported.
EIG and EMG durability
Confirm consolidated margin stays near the Q1 level with clean segment bridge disclosure.
Warn if components, freight, tariffs, mix, or integration costs erode margin without a temporary bridge.
Financing and pro forma economics
Confirm disclosed profitability, integration cost, debt cost, leverage, and deleveraging path fit AMETEK's cash profile.
Warn if leverage, debt cost, or opaque pro forma economics make acquisition returns hard to verify.
GAAP and cash validation
Confirm operating cash flow and GAAP earnings support adjusted EPS growth.
Warn if acquisition, amortization, restructuring, or integration add-backs expand or become recurring.
Risks, Invalidations, And Quality Flags
The central risk is not a weak standalone company. It is a mismatch between premium expectations and acquisition-financed evidence.
The $5.0B purchase and $4.0B term loan are large relative to AMETEK's normal bolt-on rhythm.
Higher leverage, worse profitability, elevated debt cost, or integration costs that dilute returns.
Close disclosures show margins, cash conversion, and deleveraging consistent with AMETEK's model.
Local market data imply roughly 29x the FY2026 adjusted EPS guide midpoint.
Modest order, margin, or acquisition-quality misses can compress a quality multiple.
Clean revenue, margin, cash, and Indicor evidence support the premium frame.
Electronics, metals, freight, tariffs, components, and shipping stress can pressure delivery and margins.
Cost pressure broadens before pricing or productivity offsets arrive.
Segment margins remain durable with clear cost pass-through evidence.
Adjusted EPS and adjusted operating income are central to guidance and incentive framing.
Adjusted results diverge from GAAP earnings and operating cash flow after acquisition costs rise.
GAAP, adjusted, and cash measures continue to point in the same direction.
Transcripts, rating-agency reports, current consensus, full peer work, and local 13F coverage remain incomplete.
Management tone, peer valuation, or holder concentration moves faster than the filed source lane captures.
Next source occurrence adds transcripts, rating context, peer comps, consensus, and ownership depth.
Diagnostics, Freshness, And Known Unknowns
Freshness is explicit because this page is a projection of a filed source lane, not a research refresh.
Freshness
Latest filed AME source pair generated July 4, 2026.
Local market snapshot runs through July 2, 2026 because July 4 was a U.S. holiday weekend.
AMETEK IR, Q1 release, filings, analyst coverage, and investor presentation links checked July 5, 2026.
Known unknowns
Margins, synergies, purchase-accounting effects, integration costs, leverage, and returns are not yet reported.
Full last-four-quarter call transcripts were not retrieved, limiting narrative-history confidence.
Full peer filing and valuation work plus local 13F holder coverage remain incomplete.
Links And Filings
Human-useful routes to the source lane, official AMETEK pages, SEC filings, metadata, and the local chart host.
Source-routed company view, claim map, diagnostics, and known unknowns.
Projection contract, source trail, freshness, web checks, and chart endpoints.
Official IR landing page checked July 5, 2026.
April 30, 2026 release with Q1 metrics, record orders, and raised FY2026 guidance.
Company-hosted filings page checked July 5, 2026; first page included June 2026 filings.
Official coverage list used as dated street-view context.
Company presentation with Q1 result highlights and segment model context.
Quarterly report for the period ended March 31, 2026.
Annual report for the fiscal year ended December 31, 2025.
May 6, 2026 acquisition release filed as an 8-K exhibit.
June 9, 2026 delayed-draw term loan agreement filed in June 2026.
Universal security chart route for AME while the detailed route awaits registry integration.
Local chart API: supplies the daily 9-month and weekly 5-year AME chart views.
Chart overlays: this HTML and JSON do not store page-specific overlay definitions. Shared overlay rules resolve AME separately if a rule is added.